ERBB2 and breast cancer: With respect to the promising performance in Phase I and II clinical trials for the treatment of HER2+ metastatic BC, in December 2019, the FDA granted accelerated approval for trastuzumab deruxtecan (DS-8201) [12,63,64,65].